METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS

This large, late-stage study is testing whether a weekly injection called survodutide can prevent serious liver complications in people who already have advanced scarring (cirrhosis) from fatty liver disease (NASH/MASH). About 1,590 adults will be randomly assigned to receive eit…

This is an early-stage study to test the safety of an experimental drug called ALN-CIDEB in adults with fatty liver disease (MASLD and MASH). The main goal is to see what side effects occur and how the body processes the drug. Researchers will also check if the drug reduces liver…

This study is testing two new drugs, ECC4703 and ECC0509, to see if they can reduce the amount of fat in the liver of people with MASH, a serious form of fatty liver disease. About 160 adults will be randomly assigned to receive one of the drugs, a combination of both, or a place…

This study is testing whether a minimally invasive endoscopic procedure to reduce stomach size, combined with lifestyle changes, is better than lifestyle changes alone for treating a serious fatty liver disease called MASH in people with obesity. Researchers will compare the two …

This study is testing an investigational drug called efimosfermin in people with advanced liver scarring (cirrhosis) caused by a serious fatty liver disease known as MASH. The main goals are to see if the drug is safe and well-tolerated, and to gather early signs of whether it mi…

This early-stage study aims to understand how eating food affects different versions of an experimental drug called ECC4703, which is being developed for a serious liver disease. Researchers will give single doses to about 72 healthy adults to measure how the drug moves through t…

This study aims to understand how communication between different parts of cells changes in people with fatty liver disease (MASH). Researchers will examine liver and blood samples from 20 patients undergoing weight-loss surgery to see if these cellular changes are linked to dise…